Cwm LLC lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 11.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 37,838 shares of the company’s stock after selling 4,678 shares during the period. Cwm LLC’s holdings in Elanco Animal Health were worth $987,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. LPL Financial LLC boosted its holdings in shares of Elanco Animal Health by 23.3% during the third quarter. LPL Financial LLC now owns 68,989 shares of the company’s stock worth $2,200,000 after purchasing an additional 13,047 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Elanco Animal Health by 66.1% during the third quarter. Captrust Financial Advisors now owns 1,576 shares of the company’s stock worth $50,000 after purchasing an additional 627 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Elanco Animal Health by 239.9% during the fourth quarter. Spire Wealth Management now owns 2,162 shares of the company’s stock worth $61,000 after purchasing an additional 1,526 shares during the last quarter. Bennicas & Associates Inc. boosted its holdings in shares of Elanco Animal Health by 3.4% during the fourth quarter. Bennicas & Associates Inc. now owns 16,306 shares of the company’s stock worth $463,000 after purchasing an additional 536 shares during the last quarter. Finally, Polianta Ltd acquired a new stake in shares of Elanco Animal Health during the fourth quarter worth $1,251,000.
In related news, Director R David Hoover acquired 10,000 shares of the business’s stock in a transaction on Friday, May 20th. The shares were bought at an average cost of $23.33 per share, with a total value of $233,300.00. Following the completion of the transaction, the director now directly owns 125,000 shares of the company’s stock, valued at approximately $2,916,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.40% of the company’s stock.
ELAN has been the topic of several analyst reports. Morgan Stanley decreased their price objective on Elanco Animal Health to $37.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. Stifel Nicolaus reduced their target price on Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Friday, June 24th. Finally, The Goldman Sachs Group reduced their target price on Elanco Animal Health from $37.00 to $32.00 and set a “buy” rating on the stock in a report on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.20.
NYSE:ELAN opened at $20.35 on Thursday. The business’s 50-day moving average is $22.52 and its two-hundred day moving average is $25.26. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.44 and a quick ratio of 1.41. Elanco Animal Health Incorporated has a 12 month low of $19.34 and a 12 month high of $37.49. The firm has a market capitalization of $9.65 billion, a PE ratio of -27.50, a price-to-earnings-growth ratio of 1.01 and a beta of 0.81.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.35 by $0.01. Elanco Animal Health had a positive return on equity of 6.61% and a negative net margin of 7.65%. The company had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same period last year, the company posted $0.37 earnings per share. The firm’s revenue was down 1.4% compared to the same quarter last year. Equities analysts anticipate that Elanco Animal Health Incorporated will post 1.17 EPS for the current year.
Elanco Animal Health Company Profile (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Recommended Stories
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
